

5/5/99  
  
**zimmer**

10972774  
P.O. Box 708  
Warsaw, IN 46581-0708  
219 267-6131

**Summary of Safety and Effectiveness  
Gas Plasma Sterilization**

- **Submitted by:**

Zimmer, Inc.  
P.O. Box 708  
Warsaw, IN 46581-0708

- **Prepared by:**

Theodore M. Wendt, Ph.D.  
Vice President  
Regulatory and Clinical Affairs  
Telephone: 219-372-4113  
Telefax: 219-372-4605

- **Date:**

April 27, 1999

- **Trade Name:**

Gas Plasma Sterilization

- **Common Name:**

Gas Plasma Sterilization

- **Classification Name:**

Sterilizer

- **Predicate Devices:**

*Sterrad* 100 Sterilization System, Advanced Sterilization Products  
Gas Plasma Sterilization, DePuy, Inc.  
*Abtox Plazlyte*<sup>TM</sup> Gas Plasma Sterilization, Abtox, Inc.

K 9 7 2 7 7 4

**Summary of Safety and Effectiveness  
Gas Plasma Sterilization  
(Continued)**

- **Device Description**  
*Sterrad* 100 Sterilization System

- **Intended Use**

Gas Plasma Sterilization is intended to be used for terminal sterilization of all Zimmer Ultra-High Molecular-Weight Polyethylene (UHMWPE) products as follows:

- *Trilogy*® Acetabular System (acetabular liners)
- *NexGen*® Complete Knee Solution (articular surfaces and patellas)

- **Performance Testing/Sterilization Validation**

A sterilization validation was completed and verifies achievement of a sterility assurance level (SAL) of  $10^{-6}$ .

RA07703K.510



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

MAY 5 1999

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

T.M. Wendt, Ph.D.  
Vice President  
Regulatory and Clinical Affairs  
Zimmer, Inc.  
P.O. Box 708  
Warsaw, Indiana 46581-0708

Re: K972774  
Trade Name: STERRAD Gas Plasma Sterilization of Trilogy  
Acetabular Liners and NexGen Articulator Surfaces  
(Tibial Trays) and Patellae  
Regulatory Class: II  
Product Codes: JWH, LPH, and MLR  
Dated: April 14, 1999  
Received: April 16, 1999

Dear Dr. Wendt:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - T.M. Wendt, Ph.D.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



Celia M. Witten, Ph.D., M.D.  
Director  
Division of General and  
Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if known): K 972774

Device Name: Gas Plasma Sterilization

Indications For Use:

Gas Plasma Sterilization is intended to be used for terminal sterilization of all Zimmer Ultra-High Molecular-Weight Polyethylene (UHMWPE) products as follows:

- *Trilogy*® Acetabular System (acetabular liners)
- *NexGen*® Complete Knee Solution (articular surfaces and patellas)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)


Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use  (Per 21 CFR 801.109)

OR

Over-The-Counter Use  (Optional Format 1-2-96)

RA04901C.MS

  
 (Division Sign-Off)  
 Division of General Restorative Devices  
 510(k) Number K97277